{"nctId":"NCT00462709","briefTitle":"Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks","startDateStruct":{"date":"2006-06-27","type":"ACTUAL"},"conditions":["Hereditary Angioedema"],"count":146,"armGroups":[{"label":"Open-label C1INH-nf","type":"EXPERIMENTAL","interventionNames":["Biological: C1 esterase inhibitor [human] (C1INH-nf)"]}],"interventions":[{"name":"C1 esterase inhibitor [human] (C1INH-nf)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- History of at least 1 HAE attack per month or any history of laryngeal edema\n\nIn addition, this study was open to all subjects who:\n\n* Completed participation in LEVP2005-1/B (NCT01005888) any time after the final prophylactic therapy in Part B\n* Were enrolled but not randomized in LEVP2005-1/A (NCT00289211) after Part A was closed\n* Were enrolled and randomized in LEVP2005-1/A after LEVP2005-1/B was closed to enrollment, any time after the 3-day telephone follow-up\n* Were excluded from LEVP2005-1 for any of the following reasons:\n\n  * Pregnancy or lactation\n  * Age less than 6 years\n  * Narcotic addiction\n  * Presence of anti-C1 inhibitor (C1INH) autoantibodies\n* Were not enrolled in LEVP2005-1 after enrollment in LEVP2005-1 was closed, under the following circumstances:\n\n  * Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or\n  * Had a known HAE-causing C1INH mutation, or\n  * Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator\n\nExclusion Criteria:\n\n* History of allergic reaction to C1INH or other blood products\n* Participated in any other investigational drug study within the past 30 days other than those sponsored by Lev Pharmaceuticals\n* Received blood or a blood product in the past 60 days other than C1INH-nf","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Frequency of All HAE Attacks","description":"A hereditary angioedema (HAE) attack was defined as a discrete episode during which the subject progressed from no angioedema to symptoms of angioedema.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Antigenic C1 Inhibitor (C1INH) Serum Levels","description":"Change from pre-infusion to 1 hour post-infusion in antigenic C1INH serum levels.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":"19.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"11.89"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Functional C1INH Serum Levels","description":"Change from pre-infusion to 1 hour post-infusion in functional C1INH serum levels. Functional C1INH serum levels are expressed as a percent of total detectable C1INH (i.e., functional C1INH/total detectable C1INH).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":"25.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":"18.05"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Complement C4 Serum Levels","description":"Change from pre-infusion to 1 hour post-infusion in complement C4 serum levels.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"8.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"3.61"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":146},"commonTop":["Headache","Rash","Nausea","Phlebitis"]}}}